{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-016790","form_type":"8-K","ticker":"MD","cik":"0000893949","company_name":"Pediatrix Medical Group, Inc.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.200171+00:00","generated_at":"2026-06-05T23:40:53.188489+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pediatrix Q4 GAAP loss $1.50/share; adj EPS $0.32; 2024 EBITDA guidance $200-220M","bullets":["GAAP diluted loss from continuing ops $1.50 vs income $0.29 a year ago; $168.3M non-cash impairment.","Adj EPS $0.32 (down from $0.47); net revenue $496M (-3.4% YoY); same-unit revenue -1.5%.","Q4 adjusted EBITDA $50.8M (vs $66.5M); full-year adj EBITDA $200.4M (vs $241M).","Preliminary 2024 adj EBITDA guidance $200-220M, roughly flat to down from 2023.","Net AR $272.3M; total debt $628M; no revolver borrowings; cash from ops $72.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-016790","json":"https://secwatch.observer/filing/0000950170-24-016790.json","markdown":"https://secwatch.observer/filing/0000950170-24-016790.md","text":"https://secwatch.observer/filing/0000950170-24-016790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/893949/000095017024016790/0000950170-24-016790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/893949/000095017024016790/md-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:40:53.188489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16e9c78020200e6dfc59b6b33b25ccac6d8ac8fd","claim":"Pediatrix Medical Group, Inc. reported the year ended December 31, 2023 results: revenue $1.99 billion.","evidence_excerpt":"For the year ended December 31, 2023, Pediatrix generated revenue from continuing operations of $1.99 billion, compared to $1.97 billion for the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000095017024016790/0000950170-24-016790-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$1.99 billion"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"499f1ec977157af67acf74b7b9d84869fdff5825","claim":"Pediatrix Medical Group, Inc. reported the three months ended December 31, 2023 results: revenue $496 million, net income Loss from continuing operations of $124 million, EPS loss from continuing operations of $1.50 per diluted share.","evidence_excerpt":"For the 2023 fourth quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $496 million; • Loss from continuing operations of $124 million; and • Adjusted EBITDA of $51 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000095017024016790/0000950170-24-016790-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Revenue","value":"$496 million"},{"label":"Net income","value":"Loss from continuing operations of $124 million"},{"label":"EPS","value":"loss from continuing operations of $1.50 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}